Search results

Evidence-based recommendations on avelumab (Bavencio) with axitinib for untreated advanced renal cell carcinoma in adults.

Result type

Technology appraisal guidance

Published

8 January 2026

Evidence-based recommendations on pembrolizumab (Keytruda) with axitinib (Inlyta) for untreated advanced renal cell carcinoma in adults.

Result type

Technology appraisal guidance

Published

30 September 2020

Evidence-based recommendations on axitinib (Inlyta) for previously treated advanced renal cell carcinoma in adults.

Result type

Technology appraisal guidance

Published

25 February 2015

Evidence-based recommendations on nivolumab (Opdivo) for previously treated advanced renal cell carcinoma in adults.

Result type

Technology appraisal guidance

Published

23 November 2016

Evidence-based recommendations on cabozantinib (Cabometyx) for previously treated advance renal cell carcinoma in adults.

Result type

Technology appraisal guidance

Published

9 August 2017

Evidence-based recommendations on everolimus (Afinitor) for advanced renal cell carcinoma after previous treatment.

Result type

Technology appraisal guidance

Published

22 February 2017

Evidence-based recommendations on lenvatinib (Kisplyx) with everolimus for previously treated advanced renal cell carcinoma in adults.

Result type

Technology appraisal guidance

Published

24 January 2018

Evidence-based recommendations on tivozanib (Fotivda) for treating advanced renal cell carcinoma in adults.

Result type

Technology appraisal guidance

Published

21 March 2018

In development Reference number: GID-TA11186 Expected publication date: TBC

Result type

Technology appraisal guidance

Status

In development

Browse the complete list of all our published health and social care guidance, including guidelines, NICE advice and quality standards

Evidence-based recommendations on cabozantinib (Cabometyx) with nivolumab (Opdivo) for untreated advanced renal cell carcinoma in adults.

Result type

Technology appraisal guidance

Published

10 April 2024

Discontinued Reference number: GID-TAG526

Result type

Technology appraisal guidance

Status

Discontinued

Managed access allows people to access promising new treatments that would otherwise not be recommended because it is too uncertain whether the treatment is cost-effective.

treatments. Source guidance details Comes from guidance Axitinib for treating advanced renal cell carcinoma after failure of prior...

Result type

Research recommendation

Published

9 June 2015

Evidence-based recommendations on cabozantinib (Cabometyx) for untreated advanced renal cell carcinoma in adults.

Result type

Technology appraisal guidance

Published

3 October 2018